<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02595970</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457AFR01</org_study_id>
    <nct_id>NCT02595970</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis</brief_title>
  <acronym>IPSI-PSO</acronym>
  <official_title>A 52-week (Plus Extension Until Commercialization), Single-arm Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI) at 16 Weeks, as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Participants Suffering From Moderate to Severe Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate psoriasis severity and its psychosocial impact using a novel Patient Reported
      Outcome (the Simplified Psoriasis Index SPI) at 16 weeks, as well as long-term safety,
      tolerability and efficacy of secukinumab administered subcutaneously during 52 weeks (plus
      extension) in patients with moderate to severe psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 20, 2015</start_date>
  <completion_date type="Actual">February 9, 2017</completion_date>
  <primary_completion_date type="Actual">February 9, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity component(s) of the Simplified Psoriasis Index (SPI)</measure>
    <time_frame>Change from baseline to 16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PASI (Psoriasis Area Severity Index) score</measure>
    <time_frame>week 0, 1, 2, 3, 4, 8, 12, 16, 24, 32, 40, 48, 52, EOE and FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation between PASI and proSPI (s)</measure>
    <time_frame>week 0, 1, 2, 3, 4, 8, 12, 16, 24, 32, 40, 48, 52, EOE and FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLQI (Dermatology Life Quality Index)</measure>
    <time_frame>week 0, 1, 2, 3, 4, 8, 12, 16, 24, 32, 40, 48, 52, EOE and FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPI</measure>
    <time_frame>week 0, 1, 2, 3, 4, 8, 12, 16, 24, 32, 40, 48, 52, EOE and FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>correlation between proSPI and DLQI</measure>
    <time_frame>week 0, 1, 2, 3, 4, 8, 12, 16, 24, 32, 40, 48, 52, EOE and FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between proSPI (p and i) and PASI</measure>
    <time_frame>week 0, 1, 2, 3, 4, 8, 12, 16, 24, 32, 40, 48, 52, EOE and FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self Administered PASI</measure>
    <time_frame>week 0, 1, 2, 3, 4, 8, 12, 16, 24, 32, 40, 48, 52, EOE and FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Symptom Diary (pain, itching, scaling)</measure>
    <time_frame>week 0, 1, 2, 3, 4, 8, 12, 16, 24, 32, 40, 48, 52, EOE and FU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>week 0, 1, 2, 3, 4, 8, 12, 16, 24, 32, 40, 48, 52, Extension Treatment Period, EOE and FU</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>correlation between saSPI (self assessed SPI) and DLQI</measure>
    <time_frame>week 0, 1, 2, 3, 4, 8, 12, 16, 24, 32, 40, 48, 52, EOE and FU</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>correlation between proSPI and saSPI</measure>
    <time_frame>week 0, 1, 2, 3, 4, 8, 12, 16, 24, 32, 40, 48, 52, EOE and FU</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>correlation between saSPI and PASI</measure>
    <time_frame>week 0, 1, 2, 3, 4, 8, 12, 16, 24, 32, 40, 48, 52, EOE and FU</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Ability of SPI to discriminate between responders and non-responders based on PASI response</measure>
    <time_frame>week 16</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Brief Index of Sexual Functioning (BISF)</measure>
    <time_frame>week 0, 4, 16</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Secukinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly sub cutaneous injections of 300 mg during the first month and then Monthly until Week 52 plus extension until 03/11/2016.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>weekly sub cutaneous injections of 300 mg during the first month and then monthly until week 52 plus extension until 03/11/2016.</description>
    <arm_group_label>Secukinumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with a history of chronic, moderate to severe plaque psoriasis (PASI ≥12; BSA
             (body surface area) ≥10 and IGA mod 2011 (Investigator's Global Assessment) ≥3) for at
             least 6 months

          -  patient candidates for systemic therapy.

          -  informed consent.

        Exclusion Criteria:

          -  previous treatment with agent targeting IL-17 (interleukine-17) or IL-17 receptor.

          -  recent treatment with topical treatment (2 weeks), systemic agents (4 weeks for
             methotrexate, Ciclosporine A; systemic retinoids and other systemic treatment), TNF
             (tumor necrosis factor) inhibitors (3 months) or IL-12/23 inhibitors (6 months).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PHILIPPE CELERIER</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL SAINT LOUIS - LA ROCHELLE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MARIE-ALETH RICHARD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL TIMONES - MARSEILLE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>SELIM ARACTINGI</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL COCHIN - PARIS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PIERRE ANDRE BECHEREL</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL PRIVE D'ANTONY - ANTONY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>EMMANUEL MAHE</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH VICTOR DUPOUY - ARGENTEUIL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PHILIPPE LACOUR</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL L'ARCHET - NICE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MIREILLE RUER MULARD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CABINET BATEAU BLANC - MARTIGUES</affiliation>
  </overall_official>
  <overall_official>
    <last_name>THIERRY BOYE</last_name>
    <role>Principal Investigator</role>
    <affiliation>HIA SAINTE ANNE - TOULON</affiliation>
  </overall_official>
  <overall_official>
    <last_name>ANNE DUVAL-MODESTE</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL CHARLES NICOLLE - ROUEN</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MARIE BEYLOT-BARRY</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL SAINT ANDRE - BORDEAUX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>LAURENT MISERY</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL MORVAN - BREST</affiliation>
  </overall_official>
  <overall_official>
    <last_name>VINCENT DESCAMPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL BICHAT CLAUDE BERNARD - PARIS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GUILLAUME CHABY</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU AMIENS NORD - AMIENS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>CARLE PAUL</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL LARREY - TOULOUSE</affiliation>
  </overall_official>
  <overall_official>
    <last_name>CHRISTOPHE BEDANE</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL DUPUYTREN - LIMOGES</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HERVÉ MAILLARD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CENTRE HOSPITALIER LE MANS - LE MANS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JEAN-FRANCOIS CUNY</last_name>
    <role>Principal Investigator</role>
    <affiliation>HIA LEGOUEST - METZ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Limoges cedex</city>
        <state>Haute Vienne</state>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amiens cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antony</city>
        <zip>92160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Argenteuil</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>La Rochelle</city>
        <zip>17019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Le Mans Cedex 09</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille Cedex 05</city>
        <zip>13885</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Martigues</city>
        <zip>13500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Metz</city>
        <zip>57077</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulon Cedex 9</city>
        <zip>83800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2015</study_first_submitted>
  <study_first_submitted_qc>November 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2015</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Secukinumab</keyword>
  <keyword>Simplified Psoriasis Index</keyword>
  <keyword>CAIN457A</keyword>
  <keyword>AIN457AFR01</keyword>
  <keyword>AIN457A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 9, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

